| COMPOSITION: | Each film coated tablet contains Empagliflozin 25 mg |
| FORMULATION: | TABLETS |
| STATUS: | PRESCRIPTION ONLY DRUG |
| DESCRIPTION: | EMPAFORD-25 contains Empagliflozin 25 mg, a selective SGLT2 inhibitor that lowers blood glucose levels by promoting urinary glucose excretion. It is indicated for the management of Type 2 Diabetes Mellitus and also offers proven cardiovascular and renal benefits. |
| SIDE EFFECTS: | May include urinary tract infections, genital mycotic infections, increased urination, and mild dehydration. Rarely, ketoacidosis may occur. Monitor renal function periodically. |
| DOSAGE/DIRECTIONS FOR USE: | As Prescribed by Physician |
